Edgewood Oncology, a biotech company specializing in BTX-A51 treatments for hematologic malignancies and solid tumors, has revealed fresh preclinical findings. The study, conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah…
Natera, a leader in cell-free DNA testing, presents findings from the IMvigor011 study at the EAU Congress 2024. The analysis focuses on muscle-invasive bladder cancer (MIBC) patients who tested negative…
Nucleai, a leader in spatial AI biomarkers, will present pioneering advancements in cancer diagnostics at the AACR Annual Meeting. Their posters will introduce novel AI spatial biomarkers and enhanced histopathology…
Seek Labs, a healthcare innovations company focused on next-generation molecular diagnostic systems and CRISPR-based gene therapies, is excited to welcome Dr. Randy Rasmussen, PhD, to its Board of Directors. Dr.…
The report on “Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product with Price and Volume Outlook, including Executive and Consultant Guides, and Customized Forecasting and Analysis for 2023-2027”…
Castle Biosciences, Inc. (Nasdaq: CSTL), a company focused on improving patient care through innovative tests, has announced the presentation of new data showcasing the performance of its DecisionDx-Melanoma test in…
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. have made a joint announcement regarding the recent developments related to bempedoic acid (marketed as NILEMDO®) and the bempedoic acid/ezetimibe fixed combination…
Esperion (NASDAQ: ESPR) announced today that the FDA has approved expanded labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets. This approval is based on positive…
Bristol Myers Squibb (NYSE: BMY) has announced that the European Commission (EC) has granted approval to Abecma® (idecabtagene vicleucel; ide-cel) for treating adult patients with relapsed and refractory multiple myeloma…
Merz Aesthetics, the global leader in medical aesthetics, will showcase fresh data on its product lineup and share insights into trends in medical aesthetics at the 2024 Aesthetic and Anti-Aging…
Takeda (TSE:4502/NYSE:TAK) announced today that the FDA has approved ICLUSIG® (ponatinib) through sNDA for treating adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.…
LGM Pharma, a prominent provider of customized API and CDMO services throughout the drug product lifecycle, has unveiled major upgrades to its capabilities. This includes a 50% expansion and a…